get a key
steadybase-$ company TXMD
account_id none on file
legal_name TherapeuticsMD, Inc.
ticker TXMD
cik 25743
domain therapeuticsmd.com
entry_point_account_id none on file
name TherapeuticsMD Inc.
exchange Nasdaq
sector Health Care
hq Boca Raton, FL, United States
calls 1 filings 0 executives 9 family 0
why_nownone on file
calls
Selling and marketing costs were $23.7 million for the second quarter, a decrease of $8.5 million for 26.4% compared to the second quarter of 2021 due to lower brand spending for Invexi and Overa, reduced compensation and employee benefit expense, and lower consulting expenditures, partially offset by higher education, conference, and software development costs.

Aug 15, 2022 / receipt, needs a key / Michael Donegan, CFO | earnings call 2022-08-15 | transcript 9308a1fd-2990-46dc-8378-1b5fabcfcff5 | chars 6461-6825 | segment 6

filingsnone on file
executives
Honorable Tommy Thompson Chairman of the Board - receipt
Hugh O'Dowd CEO - receipt
Justin Roberts director - receipt
Mark Glickman Chief Commercial Officer - receipt
Marlan Walker Chief Executive Officer - receipt
Michael Donegan CFO - receipt
Randall S. Stanicky director - receipt
Robert Cambridge Chief Financial Officer - receipt
Tommy G. Thompson Chairman - receipt
familynone on file
upcoming
2026-11-11 earnings call scheduled ir
changes
2023-01-06 Chief Executive Officer, appointed sec_8k
2022-09-12 Chairman of the Board, appointed sec_8k
2022-08-29 director, appointed sec_8k
2021-12-20 Chief Executive Officer, appointed sec_8k
2015-03-18 director, departed sec_8k
2013-12-18 director, appointed sec_8k
2012-05-17 Chairman, appointed sec_8k
2010-06-15 Chief Financial Officer, appointed sec_8k
2010-06-04 Chief Executive Officer, appointed sec_8k
mcp_package_hint
steadybase-$